Search NRIX
Nurix Therapeutics, Inc.
NasdaqGM · CIK 1549595
Last close22.99
Daily change-0.35 (-1.50%)
10 Years gain+20.94%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
NRIX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1130
Fundamental
50.4Momentum
0.0Acceleration
40.0Confidence
83.0Annual Revenue7
Quarterly Revenue25
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth22.1 / 25
Quality8.6 / 25
Capital Efficiency4.7 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
ROIC expansionROIC improved by 9.9976 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 131.679 percentage points.
Heavy share dilution · HIGHDiluted share count increased 32.9384%.
Key Metrics
Revenue Growth TTM12.6%OK
Revenue CAGR 3Y29.55%OK
Gross Margin100%OK
Operating Margin-485.4%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-63.21%OK
Incremental Operating Margin 3Y-632.73%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y32.94%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Nov 30, 2025 | $83.98M | $83.98M | -$285.67M | -$249.47M | -$263.47M | 100% | -340.16% | -313.73% | -63.68% | 86.67M |
| 2025 FY Nov 30, 2024 | $54.55M | $54.55M | -$213.03M | -$172.58M | -$181.86M | 100% | -390.52% | -333.38% | -59.8% | 67.12M |
| 2025 FY Nov 30, 2023 | $76.99M | $76.99M | -$155.06M | -$81.37M | -$89.77M | 100% | -201.41% | -116.6% | -174.48% | 54.34M |
| 2024 FY Nov 30, 2022 | $38.63M | $38.63M | -$183.87M | -$159.81M | -$172.05M | 100% | -476.01% | -445.42% | -706.2% | 48.61M |
| 2022 FY Nov 30, 2021 | $29.75M | $29.75M | -$117.89M | -$84.37M | -$90.03M | 100% | -396.26% | -302.61% | -334.38% | 42.9M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $67.25M | sum latest 4 fiscal quarters Revenue | OK | 0001549595-26-000040, 0001549595-25-000113 |
| Revenue Growth TTM | 12.6% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001549595-26-000040, 0001549595-25-000113 |
| Revenue CAGR 3Y | 29.55% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001549595-26-000016 |
| Revenue CAGR 5Y | 36.35% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001549595-26-000016 |
| Gross Profit CAGR 3Y | 29.55% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001549595-26-000016 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001549595-26-000040, 0001549595-25-000113 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001549595-26-000040, 0001549595-25-000113 |
| Operating Margin | -485.4% | Operating Income / Revenue | OK | 0001549595-26-000040, 0001549595-25-000113 |
| ROIC | -63.21% | NOPAT / Average Invested Capital | OK | 0001549595-26-000040, 0001549595-25-000113 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001549595-26-000040 |
| Current Ratio | 6.34x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.61 | Revenue / Diluted Shares | OK | 0001549595-26-000040, 0001549595-25-000113 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |